Abstract
Tumor-specific antigens for leukemia cells have been sought for the past
decades, but none of cell surface markers met sufficient criteria as a
'phenotypic signature'. Here we suggest that JL1 antigen can be efficiently used
for diagnosis and treatment. JL1 is a human thymocyte differentiation antigen
strictly confined to a CD4+CD8+ double positive subpopulation of cortical
thymocytes. Despite its restricted distribution in normal tissues and cells, the
expression of JL1 is highly associated with hematopoietic malignancies,
particularly various types of leukemia such as T-lineage acute lymphoblastic
leukemia (T-ALL), non-T-ALL, and acute myelocytic leukemia (AML). The expression
of JL1 antigen was observed in 75.6% of leukemic cases (117 out of 154 leukemic
patients tested) with a high mean fluorescence intensity on flow cytometric
analysis and confirmed by immunoblotting. Since JL1 antigen is selectively
expressed on the surface of human leukemic cells, but not on mature human
peripheral blood cells and normal bone marrow cells, anti-JL1 mAb can be used as
a reagent of choice in the routine diagnosis of various types of leukemia,
providing an excellent candidate for the treatment of these diseases.